Compare Tempus AI (TEM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs TG Therapeutics Inc — how do they compare? Tempus AI trades at $54.46 (market cap $10.05B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Tempus AI is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| TEM | TGTX | |
|---|---|---|
Market Cap | $10.05B | $7.64B |
Sector | Broad Market / Factor | Health |
52-Week High | $103.25 | $59.06 |
52-Week Low | $41.55 | $26.94 |
Enterprise Value | $10.68B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $54.61, down 0.82% with a bullish technical outlook despite negative profitability. The company shows strong revenue growth with 2026 revenue guidance raised to $1.4B, though net losses persist. Recent Q2 earnings beat expectations with a narrower loss of $0.04 per share versus $0.14 expected. Technical indicators show bullish momentum with support at $54 and resistance at $57.
Investment outlook balances growth potential against profitability challenges. Analyst consensus is strongly bullish with 61.5% buy ratings and $61.57 price target, representing 13% upside. Key risks include sustained negative cash flow from operations and high valuation multiples amid ongoing losses. The Personalis acquisition expands MRD testing capabilities but integration execution remains a watchpoint.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
